Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403086 | 0.89 | CYP2C9 (0.46) | CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14324165 | 0.89 | ANO1 (0.46) | ANO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2400793 | 0.89 | MEN1 (0.42) | ANO1MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL6120024 | 0.88 | ANO1 (0.48) | ANO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL14764123 | 0.86 | ALOX5 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2402739 | 0.86 | MEN1 (0.53) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL2840896 | 0.85 | ANO1 (0.50) | ANO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL6119378 | 0.85 | ANO1 (0.43) | ANO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12318452 | 0.85 | ANO1 (0.43) | ANO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2401105 | 0.84 | MEN1 (0.43) | ANO1MEN1KMT2APRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20160136172-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160136172-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160130259-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130259-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2014209727-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209726-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034047-A1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033901-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-2542545-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120328569-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. | 2012-12-27 | — | — | US | disclosed |
| WO-2011106992-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011106992-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011106986-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011106986-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136172-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | GTF3C5, HCCS, EIF2AK2 | ANO1 4677/4885ALDH1A1 297/4885MEN1 4787/4885 |
| US-20120328569-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | HCCS, EIF2AK2, RNGTT | ANO1 4360/4885ALDH1A1 1276/4885MEN1 4851/4885 |
| US-20160130259-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | GTF3C5, HCCS, EIF2AK2 | ANO1 4677/4885ALDH1A1 297/4885MEN1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.